Online Figure Legends

Online Figure S1. Schematic of groups and interventions. ATP indicates atrial tachypacing; EP, electrophysiological.

Online Figure S2. The effect of cilnidipine on heart rate variability (HRV) before and after 7-day AF. A, the average of all NN intervals (AVNN). B, the proportion of the number of pairs of NNs that differ by more than 50 ms divided by total number of NNs (pNN50). C, root mean square of the successive differences (rMSSD). The X-axis labels represent 3-hour blocks at the times of the day indicated. (n=5, 6, 5, 7 dogs for Sham, AF+Placebo, AF+Nifedipine, and AF+Cilnidipine)
* P<0.05 versus placebo and # P<0.05 versus nifedipine by 2-way ANOVA with Tukey test.

Online Figure S3. The effect of cilnidipine on expression of ion channel subunit and Ca^{2+}-handling protein and ECM genes after 7 days of AF. * P<0.05, ** P<0.01, *** P<0.001 versus sham and # P<0.05 versus AF+cilnidipine by 1-way ANOVA with Tukey test. (n=5, 9, 5, 7 dogs for Sham, AF+Placebo, AF+Nifedipine, and AF+Cilnidipine)

Online Figure S4. The assessment of left-ventricular ejection fraction (LVEF) after 21 days of AF. LVEF was reduced at end-study by an absolute value of about 15% in AF-dogs, to an equivalent extent in both placebo- and cilnidipine-treated groups. (n=8 dogs/group) ** P < 0.01 versus sham by 1-way ANOVA with Tukey test.



Online Figure 1


A
AVNN (ms)
1000
500
0
5am-8am
8am-11am
11am-2pm
2pm-5pm
5pm-8pm
8pm-11pm
11pm-2am
2am-5am
*
Cilnidipine BL
Nifedipine BL
Placebo BL
AVNN (ms)
800
600
400
200
0
* #
AF+Cilnidipine
AF+Nifedipine
AF+Placebo
B
pNN50 (%)
60
40
20
0
*
Cilnidipine BL
Nifedipine BL
Placebo BL
pNN50 (%)
50
40
30
20
10
0
* #
*
AF+Cilnidipine
AF+Nifedipine
AF+Placebo
C
rMSSD (ms)
150
100
50
0
*
Cilnidipine BL
Nifedipine BL
Placebo BL
rMSSD (ms)
80
60
40
20
0
* #
*
AF+Cilnidipine
AF+Nifedipine
AF+Placebo
* P<0.05 vs. placebo,
# P<0.05 vs. nifedipine
Online Figure 2



* P<0.05, ** P<0.01, *** P<0.001 vs. Sham # P<0.05 vs. AF+Cilnidipine

Online Figure 3



Online Figure 4